# reload+after+2024-01-23 04:39:57.886588
address1§13 Avenue Morane Saulnier
city§Vélizy-Villacoublay
zip§78140
country§France
phone§33 1 39 46 51 04
fax§33 1 30 70 05 32
website§https://www.novacyt.com
industry§Medical Devices
sector§Healthcare
longBusinessSummary§Novacyt S.A., together with its subsidiaries, provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International segments. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. The company was incorporated in 2006 and is based in Vélizy-Villacoublay, France.
fullTimeEmployees§120
companyOfficers§[{'maxAge': 1, 'name': 'Mr. James Martin McCarthy', 'age': 57, 'title': 'CFO, Acting CEO, Company Secretary & Director', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 354517, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Bryan  Close', 'title': 'Chief Operations Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Mandy  Cowling', 'title': 'Corporate & Investor Relations Manager', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. David  Franks', 'title': 'Chief Human Resources Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Paul  Oladimeji', 'title': 'Group Head of R&D', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Lyn Dafydd Rees', 'age': 50, 'title': 'Executive Director', 'yearBorn': 1973, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Steve  Gibson', 'title': 'Group Finance Director', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§10
boardRisk§5
compensationRisk§4
shareHolderRightsRisk§7
overallRisk§4
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§-1.792
priceToSalesTrailing12Months§5.6439943
currency§GBp
exchange§LSE
quoteType§EQUITY
shortName§NOVACYT S.A. EUR1/15TH (CDI)
longName§Novacyt S.A.
firstTradeDateEpochUtc§1509523200
timeZoneFullName§Europe/London
timeZoneShortName§GMT
uuid§70bb0758-a61f-33d3-90fc-85d2752856f3
recommendationKey§none
quickRatio§4.909
grossMargins§0.38507998
ebitdaMargins§-1.73714
trailingPegRatio§None
